WHO urges all nations to join global shared vaccine bid
	Chinese Covid-19 vaccine’s price ten times higher than Russian’s
	COVID-19 World Updates (August 19): J&J vaccine reaches final testing phase, approved to enter human trials

An emergency use authorization of COVID-19 vaccine allows select unapproved vaccine candidates from domestic companies to be used among people who are at high risk of getting infected. (Photo: Today News)

"We've drawn up a series of plan packages, including medical consent forms, side-effects monitoring plans, rescuing plans, compensation plans, to make sure that the emergency use is well regulated and monitored," Zheng Zhongwei, head of China's coronavirus vaccine development task force, told state-run CCTV on Saturday.

One month has handed since China formally launched the pressing use of COVID-19 vaccines on July 22, whereas the vaccines had been going by medical trials, Zheng mentioned.

Recipients who obtained their first dose since then revealed they’d few hostile reactions and none reported a fever, Today News Online said.

Zheng Zhongwei, Head of China's Coronavirus vaccine Development Task force (Photo: CGTN)

Wu, an employee of a state-owned company handling overseas construction projects along the Belt and Road Initiative (BRI) in Asian and African countries, told the Global Times on Sunday that all staff in her firm have been offered inactivated vaccine injections on a voluntary basis for free.

Wu, who took the vaccine on August 7 along with many of her colleagues, said she did not experience any adverse reactions, similar to everyone else in her group.

"My colleagues and I felt only a little dizzy on the afternoon of the vaccination, but we got over it pretty quickly. There was no local redness, swelling or pain, and we did not hear of anyone reporting a fever," said Wu, who will take her second dose on day 28 after the first shot”.

"People seem to be relaxed over the vaccination as most of us feel confident in domestically developed vaccines," she was quoted by Economic Times as saying.

One of Sinopharm's inactivated COVID-19 vaccines on August 13 was revealed to have had a low rate of adverse reactions for patients in phase I and II clinical trials, while also demonstrating immunogenicity results.

The inactivated vaccine might be efficient towards all detected strains of the virus not less than as of mid-July, with decrease probabilities and levels of hostile reactions than same-type vaccine candidates underneath analysis, Yang Xiaoming, head of Sinopharm, advised the Global Times in an earlier interview.

Yang mentioned on Saturday that greater than 20,000 individuals within the United Arab Emirates had taken inactivated COVID-19 vaccines developed by Sinopharm in section III medical trials, which have proven an excessive stage of security. The efficacy of the vaccine is underneath statement.

“The phase III trial in the UAE has had no reported cases of side effects so far,” Yang mentioned, including “volunteers joined faster than expected and the vaccine was well worth the wait”, as reported by Today News Online.

Sputnik V's third stage of trials can be called mass vaccination, said Russian developers The trials will be carried out in the Moscow Region and some 20,000 - 30,000 people will get the vaccine.

Vaccine production: a billion-dollar industry According to estimates of research firm Alliance Bernstein (headquarter in the US), the global vaccine production industry is worth $ 52 billion per year. In ...

Vietnam yet to purchase Russian Covid-19 vaccine, prepares to put indegious one on human trials The made-in-Vietnam vaccine has been confirmed to produce a good immune response against the novel coronavirus in animals and would be soon to put on .